Clinical Trials | December 09, 2025
Kelun-Biotech and Crescent Biopharma forge strategic oncology partnership
The partnership also allows both companies to explore CR-001 and SKB105 as monotherapies and in combination
The partnership also allows both companies to explore CR-001 and SKB105 as monotherapies and in combination
The collaboration will establish the MUMPMP–Agilent BioDiscovery Hub
Adverse events were similar to placebo, and no AP-101-induced antibody responses were detected
It's a development that marks a potential breakthrough for people living with the rare and debilitating disease Duchenne muscular dystrophy (DMD)
Captured microbes are then neutralized on engineered microbicidal surfaces
HYMPAVZI’s safety profile was generally favorable
While Merck can appeal, Halozyme said it expects the order to hold
76 of 180 long COVID-associated genes also linked to ME
The EMBOLD study evaluated relutrigine for patients with SCN2A and SCN8A developmental and epileptic encephalopathies
Alport Syndrome is caused by genetic mutations affecting type IV collagen in the kidneys, ears, and eyes
Subscribe To Our Newsletter & Stay Updated
